Suppr超能文献

多囊肾病中肾脏疾病变异性的决定因素。

Determinants of renal disease variability in ADPKD.

机构信息

Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Adv Chronic Kidney Dis. 2010 Mar;17(2):131-9. doi: 10.1053/j.ackd.2009.12.004.

Abstract

In common with other Mendelian diseases, the presentation and progression of autosomal dominant polycystic kidney disease (ADPKD) vary widely in the population. The typical course is of adult-onset disease with ESRD in the 6th decade. However, a small proportion has adequate renal function into the 9th decade, whereas others present with enlarged kidneys as neonates. ADPKD is genetically heterogeneous, and the disease gene is a major determinant of severity; PKD1 on average is associated with ESRD 20 years earlier than PKD2. The majority of PKD1 and PKD2 mutations are likely fully inactivating although recent studies indicate that some alleles retain partial activity (hypomorphic alleles). Homozygotes for such alleles are viable and in combination with an inactivating allele can result in early-onset disease. Hypomorphic alleles and mosaicism may also account for some cases with unusually mild disease. The degree of phenotypic variation detected in families indicates that genetic background influences disease severity. Genome-wide association studies are planned to map common variants associated with severity. Although ADPKD is a simple genetic disease, fully understanding the phenotypic variability requires consideration of influences at the genic, allelic, and genetic background level, and so, ultimately, it is complex.

摘要

与其他孟德尔疾病一样,常染色体显性多囊肾病 (ADPKD) 在人群中的表现和进展差异很大。典型的病程是成年起病,60 岁时出现终末期肾病。然而,一小部分人到 90 岁时仍有足够的肾功能,而另一些人则在新生儿期就出现肾脏增大。ADPKD 具有遗传异质性,疾病基因是严重程度的主要决定因素;PKD1 平均比 PKD2 早 20 年出现终末期肾病。尽管最近的研究表明,一些等位基因保留部分活性(低功能等位基因),但大多数 PKD1 和 PKD2 突变可能完全失活。这些等位基因的纯合子是有活力的,与失活等位基因结合可导致早发性疾病。低功能等位基因和嵌合性也可能导致一些疾病表现异常轻微的病例。在家族中检测到的表型变异程度表明遗传背景影响疾病严重程度。计划进行全基因组关联研究以绘制与严重程度相关的常见变异。尽管 ADPKD 是一种简单的遗传疾病,但要充分了解表型的可变性,需要考虑基因、等位基因和遗传背景水平的影响,因此,最终它是复杂的。

相似文献

1
Determinants of renal disease variability in ADPKD.
Adv Chronic Kidney Dis. 2010 Mar;17(2):131-9. doi: 10.1053/j.ackd.2009.12.004.
3
Genotype-phenotype of autosomal dominant polycystic kidney disease in Malta.
Eur J Med Genet. 2024 Jun;69:104934. doi: 10.1016/j.ejmg.2024.104934. Epub 2024 Mar 26.
4
Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease.
J Am Soc Nephrol. 2003 May;14(5):1164-74. doi: 10.1097/01.asn.0000061774.90975.25.
6
Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease.
JAMA. 2022 Dec 27;328(24):2412-2421. doi: 10.1001/jama.2022.22847.
10
Type of PKD1 mutation influences renal outcome in ADPKD.
J Am Soc Nephrol. 2013 May;24(6):1006-13. doi: 10.1681/ASN.2012070650. Epub 2013 Feb 21.

引用本文的文献

1
Hypertension increases PPV for polycystic kidney disease in PKD1 and PKD2 variant carriers.
HGG Adv. 2025 Jul 10;6(3):100444. doi: 10.1016/j.xhgg.2025.100444. Epub 2025 Apr 23.
2
New Mutation Associated with Polycystic Kidney Disease Type I: A Case Report.
Genes (Basel). 2024 Sep 27;15(10):1262. doi: 10.3390/genes15101262.
3
Primary Cilia Elongation in Early-Onset Polycystic Kidney Disease with 2 Hypomorphic Alleles: A Case Report.
Kidney Med. 2024 Jun 14;6(8):100857. doi: 10.1016/j.xkme.2024.100857. eCollection 2024 Aug.
4
6
Increased Expression of Orexin-A in Patients Affected by Polycystic Kidney Disease.
Int J Mol Sci. 2024 Jun 5;25(11):6243. doi: 10.3390/ijms25116243.
7
Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.
Kidney Med. 2023 Nov 27;6(1):100755. doi: 10.1016/j.xkme.2023.100755. eCollection 2024 Jan.
8
Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.
Am J Physiol Renal Physiol. 2023 Dec 1;325(6):F857-F869. doi: 10.1152/ajprenal.00056.2023. Epub 2023 Oct 12.
9
Next-Generation Sequencing-Based Genetic Diagnostic Strategies of Inherited Kidney Diseases.
Kidney Dis (Basel). 2021 Sep 29;7(6):425-437. doi: 10.1159/000519095. eCollection 2021 Nov.

本文引用的文献

1
Molecular diagnostics for autosomal dominant polycystic kidney disease.
Nat Rev Nephrol. 2010 Apr;6(4):197-206. doi: 10.1038/nrneph.2010.18. Epub 2010 Feb 23.
2
Polycystin-1 and -2 dosage regulates pressure sensing.
Cell. 2009 Oct 30;139(3):587-96. doi: 10.1016/j.cell.2009.08.045.
3
The role of the mammalian target of rapamycin (mTOR) in renal disease.
J Am Soc Nephrol. 2009 Dec;20(12):2493-502. doi: 10.1681/ASN.2008111186. Epub 2009 Oct 29.
4
Massively parallel sequencing: the next big thing in genetic medicine.
Am J Hum Genet. 2009 Aug;85(2):142-54. doi: 10.1016/j.ajhg.2009.06.022.
8
Mouse models of polycystic kidney disease.
Curr Top Dev Biol. 2008;84:311-50. doi: 10.1016/S0070-2153(08)00606-6.
9
Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.
Kidney Int. 2009 Apr;75(8):848-55. doi: 10.1038/ki.2008.686. Epub 2009 Jan 21.
10
Next-generation DNA sequencing.
Nat Biotechnol. 2008 Oct;26(10):1135-45. doi: 10.1038/nbt1486.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验